ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma
A disintegrin and metalloprotease with thrombospondin motif (ADAMTS) enzymes play important roles in cell functions including adhesion, invasion, migration, and proliferation. ADAMTS-6 is a member of the ADAMTS family; reports of its relationship with esophageal squamous cell carcinoma (ESCC) progre...
Gespeichert in:
| Veröffentlicht in: | Experimental and molecular pathology 2018-04, Vol.104 (2), p.134-139 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 139 |
|---|---|
| container_issue | 2 |
| container_start_page | 134 |
| container_title | Experimental and molecular pathology |
| container_volume | 104 |
| creator | Liu, Lan Yang, Zhaoting Ni, Weidong Xuan, Yanhua |
| description | A disintegrin and metalloprotease with thrombospondin motif (ADAMTS) enzymes play important roles in cell functions including adhesion, invasion, migration, and proliferation. ADAMTS-6 is a member of the ADAMTS family; reports of its relationship with esophageal squamous cell carcinoma (ESCC) progression are rare. It is unclear whether ADAMTS-6 could be an independent ESCC biomarker.
ADAMTS-6 expression was detected by immunohistochemistry (IHC) in 171 paraffin-embedded ESCC specimens; relationships with patients' clinicopathological features and Twist-1 expression were analyzed by the Pearson Chi-square method, respectively. Overall survival (OS) and disease-free survival (DFS) were determined using the Kaplan–Meier method and compared using the long-rank test.
ADAMTS-6 was expressed mainly in the cytoplasm and nucleus; the expression was significantly higher in tumor tissues. Increased expression of ADAMTS-6 correlated with clinical stage (P = 0.009), pT stage (P = 0.042), lymph node metastasis (P = 0.014) and recurrence (P = 0.033). There were no significant correlations between ADAMTS-6 expression and other clinicopathological parameters including age, sex, tumor size, distant metastasis, differentiation, …chemotherapy, radiotherapy, CD68 expression and epithelial mesenchymal transition (EMT) status. Kaplan–Meier survival curves revealed that upregulated expression of ADAMTS-6 indicated short OS (P = 0.001) and DFS (P = 0.002). Multivariate analysis confirmed that high ADAMTS-6 expression was an independent factor for ESCC prognosis. ADAMTS-6 expression was significantly correlated with Twist-1 expression in ESCC cancer cells (P = 0.007) and stromal cells (P |
| doi_str_mv | 10.1016/j.yexmp.2018.02.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2007987257</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014480017306044</els_id><sourcerecordid>2007987257</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-d216b8126b9a4fbfc19e54f6d6ec5c1143f6cb3ac6aec057d8db9f3d8c56b3fc3</originalsourceid><addsrcrecordid>eNp9kE9P3DAQxa2KqmyhnwCp8pFL0rGTOPGhhxX0n0TVQ-mxspzJGLzaxMHOQvn29bLQY0_vMO_NvPkxdiagFCDUh035SH_GuZQguhJkCVC_YisBWhWg6-aIrQBEXdQdwDF7m9IGADQI-YYdS123DVRqxX6vL9ffr38WivvELZ8jDR6XEHlwfA5Z5xhuppDy1E98tounaUn8wS-3nFKYb-0N2S1Pdzs7hl3iSNstRxvRT2G0p-y1s9tE7571hP36_On64mtx9ePLt4v1VYFVo5dikEL1nZCq17Z2vUOhqamdGhRhg0LUlVPYVxaVJYSmHbqh164aOmxUXzmsTtj5YW9ue7ejtJjRp30VO1FuZSRAq7tWNm22VgcrxpBSJGfm6EcbH40As-dqNuaJq9lzNSBN5ppT758P7PqRhn-ZF5DZ8PFgoPzmvadoEmZUmHFGwsUMwf_3wF-b2IvC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2007987257</pqid></control><display><type>article</type><title>ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Liu, Lan ; Yang, Zhaoting ; Ni, Weidong ; Xuan, Yanhua</creator><creatorcontrib>Liu, Lan ; Yang, Zhaoting ; Ni, Weidong ; Xuan, Yanhua</creatorcontrib><description>A disintegrin and metalloprotease with thrombospondin motif (ADAMTS) enzymes play important roles in cell functions including adhesion, invasion, migration, and proliferation. ADAMTS-6 is a member of the ADAMTS family; reports of its relationship with esophageal squamous cell carcinoma (ESCC) progression are rare. It is unclear whether ADAMTS-6 could be an independent ESCC biomarker.
ADAMTS-6 expression was detected by immunohistochemistry (IHC) in 171 paraffin-embedded ESCC specimens; relationships with patients' clinicopathological features and Twist-1 expression were analyzed by the Pearson Chi-square method, respectively. Overall survival (OS) and disease-free survival (DFS) were determined using the Kaplan–Meier method and compared using the long-rank test.
ADAMTS-6 was expressed mainly in the cytoplasm and nucleus; the expression was significantly higher in tumor tissues. Increased expression of ADAMTS-6 correlated with clinical stage (P = 0.009), pT stage (P = 0.042), lymph node metastasis (P = 0.014) and recurrence (P = 0.033). There were no significant correlations between ADAMTS-6 expression and other clinicopathological parameters including age, sex, tumor size, distant metastasis, differentiation, …chemotherapy, radiotherapy, CD68 expression and epithelial mesenchymal transition (EMT) status. Kaplan–Meier survival curves revealed that upregulated expression of ADAMTS-6 indicated short OS (P = 0.001) and DFS (P = 0.002). Multivariate analysis confirmed that high ADAMTS-6 expression was an independent factor for ESCC prognosis. ADAMTS-6 expression was significantly correlated with Twist-1 expression in ESCC cancer cells (P = 0.007) and stromal cells (P < 0.001). Patients with ESCC revealing expression of both ADAMTS-6 and Twist-1 exhibited significantly reduced OS and DFS rates than other patients.
High ADAMTS-6 expression is a useful marker of poor prognosis in patients with ESCC.</description><identifier>ISSN: 0014-4800</identifier><identifier>EISSN: 1096-0945</identifier><identifier>DOI: 10.1016/j.yexmp.2018.02.004</identifier><identifier>PMID: 29475036</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>ADAMTS Proteins - metabolism ; ADAMTS-6 ; Aged ; Biomarkers, Tumor - metabolism ; Carcinoma, Squamous Cell - metabolism ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - pathology ; Esophageal Neoplasms - metabolism ; Esophageal Neoplasms - mortality ; Esophageal Neoplasms - pathology ; Esophageal Squamous Cell Carcinoma ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Nuclear Proteins - metabolism ; Prognosis ; Twist-1 ; Twist-Related Protein 1 - metabolism</subject><ispartof>Experimental and molecular pathology, 2018-04, Vol.104 (2), p.134-139</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-d216b8126b9a4fbfc19e54f6d6ec5c1143f6cb3ac6aec057d8db9f3d8c56b3fc3</citedby><cites>FETCH-LOGICAL-c359t-d216b8126b9a4fbfc19e54f6d6ec5c1143f6cb3ac6aec057d8db9f3d8c56b3fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.yexmp.2018.02.004$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29475036$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Lan</creatorcontrib><creatorcontrib>Yang, Zhaoting</creatorcontrib><creatorcontrib>Ni, Weidong</creatorcontrib><creatorcontrib>Xuan, Yanhua</creatorcontrib><title>ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma</title><title>Experimental and molecular pathology</title><addtitle>Exp Mol Pathol</addtitle><description>A disintegrin and metalloprotease with thrombospondin motif (ADAMTS) enzymes play important roles in cell functions including adhesion, invasion, migration, and proliferation. ADAMTS-6 is a member of the ADAMTS family; reports of its relationship with esophageal squamous cell carcinoma (ESCC) progression are rare. It is unclear whether ADAMTS-6 could be an independent ESCC biomarker.
ADAMTS-6 expression was detected by immunohistochemistry (IHC) in 171 paraffin-embedded ESCC specimens; relationships with patients' clinicopathological features and Twist-1 expression were analyzed by the Pearson Chi-square method, respectively. Overall survival (OS) and disease-free survival (DFS) were determined using the Kaplan–Meier method and compared using the long-rank test.
ADAMTS-6 was expressed mainly in the cytoplasm and nucleus; the expression was significantly higher in tumor tissues. Increased expression of ADAMTS-6 correlated with clinical stage (P = 0.009), pT stage (P = 0.042), lymph node metastasis (P = 0.014) and recurrence (P = 0.033). There were no significant correlations between ADAMTS-6 expression and other clinicopathological parameters including age, sex, tumor size, distant metastasis, differentiation, …chemotherapy, radiotherapy, CD68 expression and epithelial mesenchymal transition (EMT) status. Kaplan–Meier survival curves revealed that upregulated expression of ADAMTS-6 indicated short OS (P = 0.001) and DFS (P = 0.002). Multivariate analysis confirmed that high ADAMTS-6 expression was an independent factor for ESCC prognosis. ADAMTS-6 expression was significantly correlated with Twist-1 expression in ESCC cancer cells (P = 0.007) and stromal cells (P < 0.001). Patients with ESCC revealing expression of both ADAMTS-6 and Twist-1 exhibited significantly reduced OS and DFS rates than other patients.
High ADAMTS-6 expression is a useful marker of poor prognosis in patients with ESCC.</description><subject>ADAMTS Proteins - metabolism</subject><subject>ADAMTS-6</subject><subject>Aged</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Carcinoma, Squamous Cell - metabolism</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Esophageal Neoplasms - metabolism</subject><subject>Esophageal Neoplasms - mortality</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophageal Squamous Cell Carcinoma</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nuclear Proteins - metabolism</subject><subject>Prognosis</subject><subject>Twist-1</subject><subject>Twist-Related Protein 1 - metabolism</subject><issn>0014-4800</issn><issn>1096-0945</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE9P3DAQxa2KqmyhnwCp8pFL0rGTOPGhhxX0n0TVQ-mxspzJGLzaxMHOQvn29bLQY0_vMO_NvPkxdiagFCDUh035SH_GuZQguhJkCVC_YisBWhWg6-aIrQBEXdQdwDF7m9IGADQI-YYdS123DVRqxX6vL9ffr38WivvELZ8jDR6XEHlwfA5Z5xhuppDy1E98tounaUn8wS-3nFKYb-0N2S1Pdzs7hl3iSNstRxvRT2G0p-y1s9tE7571hP36_On64mtx9ePLt4v1VYFVo5dikEL1nZCq17Z2vUOhqamdGhRhg0LUlVPYVxaVJYSmHbqh164aOmxUXzmsTtj5YW9ue7ejtJjRp30VO1FuZSRAq7tWNm22VgcrxpBSJGfm6EcbH40As-dqNuaJq9lzNSBN5ppT758P7PqRhn-ZF5DZ8PFgoPzmvadoEmZUmHFGwsUMwf_3wF-b2IvC</recordid><startdate>201804</startdate><enddate>201804</enddate><creator>Liu, Lan</creator><creator>Yang, Zhaoting</creator><creator>Ni, Weidong</creator><creator>Xuan, Yanhua</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201804</creationdate><title>ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma</title><author>Liu, Lan ; Yang, Zhaoting ; Ni, Weidong ; Xuan, Yanhua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-d216b8126b9a4fbfc19e54f6d6ec5c1143f6cb3ac6aec057d8db9f3d8c56b3fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>ADAMTS Proteins - metabolism</topic><topic>ADAMTS-6</topic><topic>Aged</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Carcinoma, Squamous Cell - metabolism</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Esophageal Neoplasms - metabolism</topic><topic>Esophageal Neoplasms - mortality</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophageal Squamous Cell Carcinoma</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nuclear Proteins - metabolism</topic><topic>Prognosis</topic><topic>Twist-1</topic><topic>Twist-Related Protein 1 - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Lan</creatorcontrib><creatorcontrib>Yang, Zhaoting</creatorcontrib><creatorcontrib>Ni, Weidong</creatorcontrib><creatorcontrib>Xuan, Yanhua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental and molecular pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Lan</au><au>Yang, Zhaoting</au><au>Ni, Weidong</au><au>Xuan, Yanhua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma</atitle><jtitle>Experimental and molecular pathology</jtitle><addtitle>Exp Mol Pathol</addtitle><date>2018-04</date><risdate>2018</risdate><volume>104</volume><issue>2</issue><spage>134</spage><epage>139</epage><pages>134-139</pages><issn>0014-4800</issn><eissn>1096-0945</eissn><abstract>A disintegrin and metalloprotease with thrombospondin motif (ADAMTS) enzymes play important roles in cell functions including adhesion, invasion, migration, and proliferation. ADAMTS-6 is a member of the ADAMTS family; reports of its relationship with esophageal squamous cell carcinoma (ESCC) progression are rare. It is unclear whether ADAMTS-6 could be an independent ESCC biomarker.
ADAMTS-6 expression was detected by immunohistochemistry (IHC) in 171 paraffin-embedded ESCC specimens; relationships with patients' clinicopathological features and Twist-1 expression were analyzed by the Pearson Chi-square method, respectively. Overall survival (OS) and disease-free survival (DFS) were determined using the Kaplan–Meier method and compared using the long-rank test.
ADAMTS-6 was expressed mainly in the cytoplasm and nucleus; the expression was significantly higher in tumor tissues. Increased expression of ADAMTS-6 correlated with clinical stage (P = 0.009), pT stage (P = 0.042), lymph node metastasis (P = 0.014) and recurrence (P = 0.033). There were no significant correlations between ADAMTS-6 expression and other clinicopathological parameters including age, sex, tumor size, distant metastasis, differentiation, …chemotherapy, radiotherapy, CD68 expression and epithelial mesenchymal transition (EMT) status. Kaplan–Meier survival curves revealed that upregulated expression of ADAMTS-6 indicated short OS (P = 0.001) and DFS (P = 0.002). Multivariate analysis confirmed that high ADAMTS-6 expression was an independent factor for ESCC prognosis. ADAMTS-6 expression was significantly correlated with Twist-1 expression in ESCC cancer cells (P = 0.007) and stromal cells (P < 0.001). Patients with ESCC revealing expression of both ADAMTS-6 and Twist-1 exhibited significantly reduced OS and DFS rates than other patients.
High ADAMTS-6 expression is a useful marker of poor prognosis in patients with ESCC.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>29475036</pmid><doi>10.1016/j.yexmp.2018.02.004</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-4800 |
| ispartof | Experimental and molecular pathology, 2018-04, Vol.104 (2), p.134-139 |
| issn | 0014-4800 1096-0945 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2007987257 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | ADAMTS Proteins - metabolism ADAMTS-6 Aged Biomarkers, Tumor - metabolism Carcinoma, Squamous Cell - metabolism Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Esophageal Neoplasms - metabolism Esophageal Neoplasms - mortality Esophageal Neoplasms - pathology Esophageal Squamous Cell Carcinoma Female Humans Kaplan-Meier Estimate Male Middle Aged Nuclear Proteins - metabolism Prognosis Twist-1 Twist-Related Protein 1 - metabolism |
| title | ADAMTS-6 is a predictor of poor prognosis in patients with esophageal squamous cell carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T01%3A53%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ADAMTS-6%20is%20a%20predictor%20of%20poor%20prognosis%20in%20patients%20with%20esophageal%20squamous%20cell%20carcinoma&rft.jtitle=Experimental%20and%20molecular%20pathology&rft.au=Liu,%20Lan&rft.date=2018-04&rft.volume=104&rft.issue=2&rft.spage=134&rft.epage=139&rft.pages=134-139&rft.issn=0014-4800&rft.eissn=1096-0945&rft_id=info:doi/10.1016/j.yexmp.2018.02.004&rft_dat=%3Cproquest_cross%3E2007987257%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2007987257&rft_id=info:pmid/29475036&rft_els_id=S0014480017306044&rfr_iscdi=true |